| 9.96 0.01 (0.1%) | 03-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.65 | 1-year : | 11.69 |
| Resists | First : | 9.97 | Second : | 10.01 |
| Pivot price | 9.96  |
|||
| Supports | First : | 9.93 | Second : | 8.26 |
| MAs | MA(5) : | 9.95 |
MA(20) : | 9.97 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 29 |
D(3) : | 26.2 |
| RSI | RSI(14): 47.1 |
|||
| 52-week | High : | 10.01 | Low : | 9.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DMII ] has closed above bottom band by 41.5%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 9.99 - 10.03 | 10.03 - 10.07 |
| Low: | 9.83 - 9.88 | 9.88 - 9.92 |
| Close: | 9.88 - 9.95 | 9.95 - 10.03 |
Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Fri, 06 Mar 2026
Drugs Made In America Acquisition Corp. confirms trust account balance after affiliate irregularities - Investing.com Australia
Fri, 06 Mar 2026
Sponsor overpayment leads to CEO change at Drugs Made In America II (DMII) - Stock Titan
Thu, 30 Oct 2025
Challenging Pfizer, Novo Nordisk Offers Up-to-$9B for Metsera - Genetic Engineering and Biotechnology News
Wed, 08 Oct 2025
Families of Trump and commerce secretary stand to benefit from U.S. drug overhaul: WSJ - Seeking Alpha
Thu, 02 Oct 2025
Drugs Made In America Acquisition II Corp. completes $500 million IPO and private placement - Investing.com
Thu, 25 Sep 2025
Drugs Made In America Acquisition II prices $500 million IPO at $10 per unit - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Shell Companies
|
|
| Shares Out | 66 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 17.6 (%) |
| Held by Institutions | 53.9 (%) |
| Shares Short | 84 (K) |
| Shares Short P.Month | 104 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -38.31 |
| Price to Sales | 0 |
| Price to Cash Flow | -1120.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|